[62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review

Objective: To report a case of gross haematuria in a patient on leflunomide. In 1998, the USA Food and Drug Administration approved leflunomide for the treatment of active rheumatoid arthritis. Leflunomide is classified as a disease-modifying anti-rheumatic drug (DMARD), which has immunomodulatory,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vincent Khor, Kwok Ying Lie
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2018
Materias:	Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/ac67fb1fcf304d33a374d1cb6e0ee89f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac67fb1fcf304d33a374d1cb6e0ee89f
record_format	dspace
spelling	oai:doaj.org-article:ac67fb1fcf304d33a374d1cb6e0ee89f2021-12-02T13:03:32Z[62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review2090-598X10.1016/j.aju.2018.10.015https://doaj.org/article/ac67fb1fcf304d33a374d1cb6e0ee89f2018-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2090598X18301098https://doaj.org/toc/2090-598XObjective: To report a case of gross haematuria in a patient on leflunomide. In 1998, the USA Food and Drug Administration approved leflunomide for the treatment of active rheumatoid arthritis. Leflunomide is classified as a disease-modifying anti-rheumatic drug (DMARD), which has immunomodulatory, anti-inflammatory, analgesics, and antipyretic effects. Methods: We report an atypical case of a 70-year-old woman who presented with two isolated episodes of gross haematuria with mild thrombocytopaenia, 5 months after she was started on leflunomide. Cystoscopy showed an abnormal bladder neovascularisation pattern with bleeding from one of the small vessels. Based on the timeline and clinical course, we hypothesised that the gross haematuria and neovascularisation was associated with the use of leflunomide. An electronic search of PubMed/MEDLINE was performed with the text words ‘Leflunomide’, ‘haematuria’, ‘angiogenesis’, ‘neovascularization’, and ‘DMARD’. The relevant articles were selected for review. Results: The literature review revealed one report of gross haematuria that was associated with leflunomide, and this was due to its interaction with warfarin. There were no reports that related to an abnormal bladder neovascularisation with leflunomide as seen in our case. She presented with two episodes of gross haematuria after she was started on leflunomide and presented to our hospital on her second episode. The second episode of gross haematuria was severe, which required blood transfusions, multiple manual bladder washouts, and cystodiathermy in the operating theatre. Rigid cystoscopy showed an abnormal neovascularisation pattern throughout the bladder. The haematuria stopped subsequently. The thrombocytopaenia improved, and haematuria did not recur after the cessation of leflunomide. A follow-up cystoscopy 3 months later showed a similar neovascularisation pattern with no active bleeding. Conclusion: The literature shows that leflunomide has anti-proliferative and anti-angiogenesis activities. To the best of our knowledge, we have not been able find a reasonable explanation for the observed bladder neovascularisation pattern and its association with DMARD, particularly leflunomide.Vincent KhorKwok Ying LieTaylor & Francis GrouparticleDiseases of the genitourinary system. UrologyRC870-923ENArab Journal of Urology, Vol 16, Iss , Pp S30- (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the genitourinary system. Urology RC870-923
spellingShingle	Diseases of the genitourinary system. Urology RC870-923 Vincent Khor Kwok Ying Lie [62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review
description	Objective: To report a case of gross haematuria in a patient on leflunomide. In 1998, the USA Food and Drug Administration approved leflunomide for the treatment of active rheumatoid arthritis. Leflunomide is classified as a disease-modifying anti-rheumatic drug (DMARD), which has immunomodulatory, anti-inflammatory, analgesics, and antipyretic effects. Methods: We report an atypical case of a 70-year-old woman who presented with two isolated episodes of gross haematuria with mild thrombocytopaenia, 5 months after she was started on leflunomide. Cystoscopy showed an abnormal bladder neovascularisation pattern with bleeding from one of the small vessels. Based on the timeline and clinical course, we hypothesised that the gross haematuria and neovascularisation was associated with the use of leflunomide. An electronic search of PubMed/MEDLINE was performed with the text words ‘Leflunomide’, ‘haematuria’, ‘angiogenesis’, ‘neovascularization’, and ‘DMARD’. The relevant articles were selected for review. Results: The literature review revealed one report of gross haematuria that was associated with leflunomide, and this was due to its interaction with warfarin. There were no reports that related to an abnormal bladder neovascularisation with leflunomide as seen in our case. She presented with two episodes of gross haematuria after she was started on leflunomide and presented to our hospital on her second episode. The second episode of gross haematuria was severe, which required blood transfusions, multiple manual bladder washouts, and cystodiathermy in the operating theatre. Rigid cystoscopy showed an abnormal neovascularisation pattern throughout the bladder. The haematuria stopped subsequently. The thrombocytopaenia improved, and haematuria did not recur after the cessation of leflunomide. A follow-up cystoscopy 3 months later showed a similar neovascularisation pattern with no active bleeding. Conclusion: The literature shows that leflunomide has anti-proliferative and anti-angiogenesis activities. To the best of our knowledge, we have not been able find a reasonable explanation for the observed bladder neovascularisation pattern and its association with DMARD, particularly leflunomide.
format	article
author	Vincent Khor Kwok Ying Lie
author_facet	Vincent Khor Kwok Ying Lie
author_sort	Vincent Khor
title	[62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review
title_short	[62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review
title_full	[62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review
title_fullStr	[62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review
title_full_unstemmed	[62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review
title_sort	[62] the mystery of gross haematuria in a patient on leflunomide: a case report and literature review
publisher	Taylor & Francis Group
publishDate	2018
url	https://doaj.org/article/ac67fb1fcf304d33a374d1cb6e0ee89f
work_keys_str_mv	AT vincentkhor 62themysteryofgrosshaematuriainapatientonleflunomideacasereportandliteraturereview AT kwokyinglie 62themysteryofgrosshaematuriainapatientonleflunomideacasereportandliteraturereview
_version_	1718393523618709504

[62] The mystery of gross haematuria in a patient on leflunomide: A case report and literature review

Ejemplares similares